ReShape Lifesciences Net Long-Term Debt 2015-2024 | RSLS
ReShape Lifesciences net long-term debt from 2015 to 2024. Net long-term debt can be defined as the net amount of long term debt issued and repaid. This field is either calculated as the sum of the long term debt fields or used if a company does not report debt issued and repaid separately
| ReShape Lifesciences Annual Net Long-Term Debt (Millions of US $) |
|
|---|---|
| 2024 | $1 |
| 2023 | $N/A |
| 2022 | $N/A |
| 2021 | $-10 |
| 2020 | $10 |
| 2019 | $-10 |
| 2018 | $N/A |
| 2017 | $N/A |
| 2016 | $N/A |
| 2015 | $5 |
| 2014 | $2 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED INSTRUMENTS | $0.004B | $0.008B |
| ReShape Lifesciences Inc. provides weight-loss solutions. It offers an integrated portfolio of proven products and services which manage and treat obesity and metabolic disease. ReShape Lifesciences Inc., formerly known as Obalon Therapeutics, is based in SAN CLEMENTE, CA. | |||